Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

Exclusion Criteria

• •Receiving monoclonal antibodies or biotherapies altering the immune response, other than anti-CD20 antibodies in the chemotherapy protocol.
• •Uncontrolled bacterial, viral or fungal infection less than 7 days.
• •Previous vaccination with PCV13 or PPV23 (unless PCV13 was administered in childhood. The last injection must be performed at least five years ago).
• •Preexisting condition that altered the immune response: splenectomy, HIV, primary or secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not included in the chemotherapy.
• •Patient who already received chemotherapy for malignancy in the previous 2 years before the inclusion.
• •Major blood clotting disorders preventing intramuscular injection.
• •Medical history of anaphylactic reaction to vaccination.
• •Known allergy to one of the vaccine components.
• •Involvement to another vaccine biomedical research.
• •Protected person.
• •Pregnant women or women of childbearing age without appropriate contraceptive measures.
• •Perfusion of polyvalent immunoglobulins during follow-up.
• •Participants with hypersensitivity to aluminum phosphate, phenol or CRM197 protein, protein derived from Corynebacterium diphtheria.